Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niaspan for Dyslipidemia in Metabolic Syndrome
NCT00659321Phase 3Completed
- Sponsor
- GWT-TUD
- Start
- Jan 2007
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dyslipidemia and metabolic syndrome comparing Niaspan with Placebo (2 arms). Primary endpoint: Effectiveness of nicotine acid in treatment of postprandial dyslipidemia at 16 weeks. Started Jan 2007; status: completed.
02
Drugs
niacin
03
Conditions
dyslipidemiametabolic syndrome
Beyond the preview
Go deeper on NCT00659321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00659321.